A History of Innovation
1973
Recombinant DNA Technology Emerges
Scientists Stanley Cohen and Herbert Boyer developed the first methods to splice DNA and create recombinant organisms.
1976
America’s First Biotech Company Founding
The company was the first to commercialize recombinant DNA technology. This breakthrough laid the foundation for the modern biotech industry.
1978
Synthetic Human Insulin Developed
This innovation showed that genetically engineered human proteins could be safely and reliably used to replace animal-derived therapies.
1970s-Present
Advances in Immune Therapies and Precision Medicine
These therapies have transformed cancer care from a “one-size-fits-all” approach to a personalized strategy that significantly improves survival rates.
1982
FDA Approves the First Biotechnology Drug
This milestone enabled the mass production of synthetic, human-identical insulin using genetically modified E. coli, offering a purer, more reliable supply for diabetics.
1982
Small Business Innovation Research (SBIR) Program Established
Congress created SBIR to support small businesses in developing innovative technologies with commercial potential, strengthening U.S. competitiveness by bridging early-stage research and market-ready innovation.
1983
Congress Enacts the Orphan Drug Act
This act incentivized the development of treatments for rare diseases, significantly expanding innovation for underserved patient populations.
1986
FDA Approves the First Recombinant Hepatitis B Vaccine
This vaccine had a profound public health impact, dramatically reducing rates of chronic hepatitis B infection, cirrhosis, and liver cancer worldwide.
1986-1990
Human Genome Project Initiated
A massive, publicly funded effort to map and sequence the entire human genome was planned and launched, contributing to genomics, personalized medicine, and countless biotech innovations.
1987
FDA Approves the First Biotech Drug for Heart Attacks
This landmark revolutionized emergency cardiovascular care, offering a more effective alternative to existing treatments.
1990s
Genomics and Gene Therapies Begin
The first federally approved human gene therapy trial and rapid advances in mapping, sequencing, and genomic tools, established biotechnology as central to the future of medicine.
1992
FDA Establishes the Accelerated Approval Pathway
This program allowed earlier approval of therapies for serious conditions based on surrogate endpoints, speeding patient access while maintaining scientific rigor.
1992
Congress Passes the Prescription Drug User Fee Act (PDUFA)
The ability of the FDA to collect fees from drug developers to speed the review process became a crucial mechanism in a more efficient regulatory pathway.
2000-2003
Human Genome Project Milestones
In 2000, a draft of the human genome was announced. Completed in 2003, this genetic blueprint of our species marked one of the most significant scientific achievements ever.
2000s
Biotech Transitions from Research to Global Industry
As biotechnology became a driver of modern medicine and commercial innovation, the decade saw rapid growth in monoclonal antibodies, biologics, and platform‑based drug development, alongside major investment.
2012
Establishment of Rare Pediatric Disease Priority Review Voucher (PPRV) Program
This program encourages the development of new treatments for rare pediatric diseases by awarding sponsors a transferable voucher upon approval of an eligible drug.
2012
Commercialization of Gene Editing
Gene editing provides an accessible, precise tool for altering genomes. It led to numerous start-ups and research pathways.
2013
Supreme Court Rules Human Genes Cannot Be Patented
This landmark ruling opened the field of genetic diagnostics to broader competition, lowering barriers to innovation and enabling more accessible, affordable genetic testing across the biotech sector.
2016
Congress Enacts the 21st Century Cures Act
This significantly increased funding for biomedical research, including NIH initiatives, and accelerated pathways for drug development and modern clinical trial designs.
2017
FDA Approves the First CAR-T Cell Therapy for Cancer
This milestone demonstrates the power of living medicines and launches a new era of personalized immunotherapy.
2020–2021
Advancement of mRNA Technology
The global deployment of mRNA technology marked the first large‑scale demonstration of programmable, RNA‑based therapeutics. Its success accelerated mRNA’s adoption for vaccines, oncology, and rare-disease therapies far beyond infectious disease.
2020s
Advances in Genomics & AI Convergence
The biotech industry has spearheaded advances in sequencing technology; AI for protein structure prediction and drug discovery; and synthetic biology.